Boehringer Ingelheim GMBH is investing further in the Austrian cancer start-up ViraTherapeutics in a deal that will give the German pharma access to a next-generation oncolytic virus therapy platform and lead candidate VSV-GP (vesicular stomatitis virus glycoprotein), along with an option to buyout ViraTherapeutics outright.
In the deal announced Sept. 28, Boehringer agreed to pay up to €210m for the option to buy ViraTherapeutics after...








